Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more

Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

7.848M

52 Wk Range

$0.25 - $39.84

Previous Close

$0.33

Open

$0.34

Volume

309,703

Day Range

$0.32 - $0.34

Enterprise Value

3.916M

Cash

3.45M

Avg Qtr Burn

-2.689M

Insider Ownership

61.49%

Institutional Own.

6.64%

Qtr Updated

03/31/25